Clinical Trial Update: Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of single and multiple doses of ISIS 353512 in healthy volunteers completed; no efficacy data reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Diseases

Drugs mentioned

• ISIS 353512 (ISIS-353512)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Inflammatory Diseases | Phase 1 | Status: COMPLETED